JP2016518305A5 - - Google Patents

Info

Publication number

JP2016518305A5

JP2016518305A5 JP2015551199A JP2015551199A JP2016518305A5 JP 2016518305 A5 JP2016518305 A5 JP 2016518305A5 JP 2015551199 A JP2015551199 A JP 2015551199A JP 2015551199 A JP2015551199 A JP 2015551199A JP 2016518305 A5 JP2016518305 A5 JP 2016518305A5

Authority

JP

Japan

Prior art keywords

alkyl

optionally substituted

compound

general formula

inhibitor

Prior art date

2014-01-07

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 125000000217 alkyl group Chemical group 0.000 claims 17
• 150000001875 compounds Chemical class 0.000 claims 14
• 239000003446 ligand Substances 0.000 claims 8
• 239000003814 drug Substances 0.000 claims 6
• 125000003107 substituted aryl group Chemical group 0.000 claims 5
• 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 4
• 239000013078 crystal Substances 0.000 claims 4
• 239000000203 mixture Substances 0.000 claims 4
• 239000000651 prodrug Substances 0.000 claims 4
• 229940002612 prodrug Drugs 0.000 claims 4
• 150000003839 salts Chemical class 0.000 claims 4
• 239000012453 solvate Substances 0.000 claims 4
• JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 claims 3
• 206010022000 influenza Diseases 0.000 claims 3
• 229910052760 oxygen Inorganic materials 0.000 claims 3
• 239000008194 pharmaceutical composition Substances 0.000 claims 3
• 238000003419 tautomerization reaction Methods 0.000 claims 3
• 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 2
• 101800004538 Bradykinin Proteins 0.000 claims 2
• QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims 2
• 102100035792 Kininogen-1 Human genes 0.000 claims 2
• 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims 2
• 229940122142 Lipoxygenase inhibitor Drugs 0.000 claims 2
• 229940123424 Neuraminidase inhibitor Drugs 0.000 claims 2
• 229940123066 Polymerase inhibitor Drugs 0.000 claims 2
• 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 2
• 239000003242 anti bacterial agent Substances 0.000 claims 2
• 239000002260 anti-inflammatory agent Substances 0.000 claims 2
• 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
• 230000003115 biocidal effect Effects 0.000 claims 2
• QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims 2
• 229930003827 cannabinoid Natural products 0.000 claims 2
• 239000003557 cannabinoid Substances 0.000 claims 2
• 229940125400 channel inhibitor Drugs 0.000 claims 2
• 239000003795 chemical substances by application Substances 0.000 claims 2
• 125000005843 halogen group Chemical group 0.000 claims 2
• 230000002265 prevention Effects 0.000 claims 2
• 239000002911 sialidase inhibitor Substances 0.000 claims 2
• 229910052717 sulfur Inorganic materials 0.000 claims 2
• 125000001960 7 membered carbocyclic group Chemical group 0.000 claims 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
• 241000712892 Arenaviridae Species 0.000 claims 1
• 241000711573 Coronaviridae Species 0.000 claims 1
• 102100031780 Endonuclease Human genes 0.000 claims 1
• 108010042407 Endonucleases Proteins 0.000 claims 1
• 241000711950 Filoviridae Species 0.000 claims 1
• 241000710781 Flaviviridae Species 0.000 claims 1
• 241000700586 Herpesviridae Species 0.000 claims 1
• 241000712464 Orthomyxoviridae Species 0.000 claims 1
• 241000711504 Paramyxoviridae Species 0.000 claims 1
• 241000150350 Peribunyaviridae Species 0.000 claims 1
• 241000709664 Picornaviridae Species 0.000 claims 1
• 241000711931 Rhabdoviridae Species 0.000 claims 1
• 208000019802 Sexually transmitted disease Diseases 0.000 claims 1
• 241000710924 Togaviridae Species 0.000 claims 1
• 241000700605 Viruses Species 0.000 claims 1
• 239000000654 additive Substances 0.000 claims 1
• 125000003118 aryl group Chemical group 0.000 claims 1
• 238000003556 assay Methods 0.000 claims 1
• 239000000969 carrier Substances 0.000 claims 1
• 125000000753 cycloalkyl group Chemical group 0.000 claims 1
• 230000000694 effects Effects 0.000 claims 1
• 238000002866 fluorescence resonance energy transfer Methods 0.000 claims 1
• 229910052736 halogen Inorganic materials 0.000 claims 1
• 125000000623 heterocyclic group Chemical group 0.000 claims 1
• 125000001424 substituent group Chemical group 0.000 claims 1
• 0 CC(C)(*)C(N(C(C(*)N(*)C1=O)[Rn])C1=C1O*)=NC1=O Chemical compound CC(C)(*)C(N(C(C(*)N(*)C1=O)[Rn])C1=C1O*)=NC1=O 0.000 description 1